Key clinical point: Patients with unresectable hepatocellular carcinoma (uHCC) and modified albumin-bilirubin (mALBI) grade 1 or 2a show better therapeutic response to atezolizumab plus bevacizumab (ATE+BEV) treatment than those with uHCC and mALBI grade 2b or 3.
Major finding: Patients with mALBI grade 1+2a vs mALBI grade 2b+3 had a significantly higher objective response rate (26.2% vs 3.4%; P = .02) and longer median progression-free survival (10.5 vs 3.0 months; hazard ratio 2.086; P < .01) with ATE+BEV.
Study details: This retrospective observational study included 71 patients who received ATE+BEV for uHCC and had an mALBI grade of 1+2a (n = 42) or 2b+3 (n = 29).
Disclosures: No source of funding was reported. The authors declared no conflicts of interest.
Source: Tomonari T et al. Initial therapeutic results of atezolizumab plus bevacizumab for unresectable advanced hepatocellular carcinoma and the importance of hepatic functional reserve. Cancer Med. 2022 (Aug 14). Doi: 10.1002/cam4.5145
